Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2004
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma
Gheath Alatrash, Thomas E Hutson, Luis Molto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 10, 2011
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma
Valerie P Grignol, Thomas Olencki, Kiran Relekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy
Kimberly A Varker, Sri Vidya Kondadasula, Michael R Go, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 29, 2010
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010
Gregory B Lesinski, William E Carson, Elizabeth A Repasky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
Paul Monk, Elaine Lam, Amir Mortazavi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 29, 2012
Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue
Lei He, John C Grecula, Yonghua Ling, et al.
Cancer Immunology, Immunotherapy : CII
|
September 2, 2016
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C Duggan, Caroline Jochems, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 31, 2014
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma
Elaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma
Joseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 16, 2004
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma
Gheath Alatrash, Thomas E Hutson, Luis Molto, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 10, 2011
A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma
Valerie P Grignol, Thomas Olencki, Kiran Relekar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2006
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy
Kimberly A Varker, Sri Vidya Kondadasula, Michael R Go, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 29, 2010
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010
Gregory B Lesinski, William E Carson, Elizabeth A Repasky, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 7, 2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma
Paul Monk, Elaine Lam, Amir Mortazavi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
August 29, 2012
Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue
Lei He, John C Grecula, Yonghua Ling, et al.
Cancer Immunology, Immunotherapy : CII
|
September 2, 2016
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C Duggan, Caroline Jochems, Renee N Donahue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2017
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K Choueiri, Susan Halabi, Ben L Sanford, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
July 31, 2014
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma
Elaine T Lam, Michael K K Wong, Neeraj Agarwal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
December 10, 2013
A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma
Joseph Markowitz, Eric A Luedke, Valerie P Grignol, et al.
Page
of 7